New combo attack on liver cancer: radiation plus immune booster

NCT ID NCT05366829

Recruiting now Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a drug called tislelizumab after radiation or other local treatments helps people with liver cancer that cannot be surgically removed. The goal is to see if this combination can keep the cancer from growing or spreading for a longer period of time. The drug works by helping the body's own immune system fight the cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10451, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CARCINOMA, HEPATOCELLULAR LIVER CELL CARCINOMA